In Brief: Interneuron
Interneuron: Transfer of sublicense of Servier dexfenfluramine to AHP is progressing, following its purchase of American Cyanamid, who is the original sublicenser of dexfenfluramine from Interneuron, company reports. Under the licensing agreement between Servier and Interneuron, "Servier has the right to withdraw its consent to the sublicense in the event that any entity acquires stock in American Cyanamid sufficient to elect a majority" of Cyanamid's board of directors, according to Interneuron's 1994 annual report...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth